TGA Rejects GP Isotretinoin Prescribing Change
The Therapeutic Goods Administration has rejected a Royal Australian College of General Practitioners application to let GPs start oral isotretinoin treatment.
Updated on Nov. 10, 2026 in Beauty

Live Poll
Do you trust your regular GP to safely prescribe specialist-only medications?
The Therapeutic Goods Administration has rejected an application from the Royal Australian College of General Practitioners to allow GPs to initiate oral isotretinoin, a medication currently restricted to dermatologists for first prescriptions. The interim decision is open for consultation until 4 December.
Why it matters
Isotretinoin is used to treat severe acne, and the decision determines whether patients can start treatment with a GP or must see a dermatologist. The TGA cited concerns about teratogenicity, clinical complexity and the expansion of existing telehealth prescribing of the medication.
The TGA received 393 responses to the application, and 383 of them opposed overturning the restrictions. New Zealand has allowed GPs and nurse practitioners to prescribe isotretinoin since 2009, and the TGA's interim decision remains open for consultation until 4 December.
The players
Therapeutic Goods Administration
The TGA is Australia's federal regulator responsible for assessing and approving medicines, medical devices and other therapeutic goods for supply in the country.
Royal Australian College of General Practitioners
The RACGP is the peak professional body for general practitioners in Australia, representing more than 50,000 GPs across the country.
The details
The RACGP lodged its application in June 2025 seeking to remove restrictions that limit initial prescribing of oral isotretinoin to dermatologists. The TGA issued a safety notification last year calling for a mental health assessment before initiation, and the college has launched a campaign urging GPs to submit responses to the consultation or contribute de-identified clinical examples.
Timeline
June 2025: RACGP lodged its application to extend isotretinoin prescribing.
Last year (2025): TGA issued an isotretinoin safety notification.
Early November 2026: TGA published its interim decision rejecting GP initiation.
4 December 2026: TGA consultation on the interim decision closes.
Culture Shift
Australia's decision contrasts with New Zealand, which has allowed GPs and nurse practitioners to prescribe isotretinoin since 2009. The debate reflects a wider question about how far primary care should extend into specialist-controlled treatments.
Patients with severe acne may still need to wait for a dermatologist appointment before starting isotretinoin in Australia. GPs can contribute de-identified clinical examples to the RACGP submission or make a direct submission to the TGA before the consultation closes.
The takeaway
Patients seeking isotretinoin in Australia should continue to consult a dermatologist for initial prescribing while the consultation is open. Those interested in the outcome can follow the TGA consultation before the 4 December deadline.
What happens next
The TGA consultation on its interim decision closes on 4 December 2026, after which the regulator will consider submissions before making a final determination.
Further reading
Explore more on Beauty treatments and how prescribing rules shape access to skincare medicines.
More information
Read the TGA interim decision and consultation details on the Therapeutic Goods Administration website.
Source note: This article includes information reported by Racgp.
Live Poll
Do you trust your regular GP to safely prescribe specialist-only medications?






